Histopathological features of systemic sclerosis-associated myopathy: A scoping review
- PMID: 33971337
- DOI: 10.1016/j.autrev.2021.102851
Histopathological features of systemic sclerosis-associated myopathy: A scoping review
Abstract
Background: Scleromyositis (SM) is an emerging subset of myositis associated with features of systemic sclerosis (SSc) but it is currently not recognized as a distinct histopathological subset by the European NeuroMuscular Center (ENMC). Our aim was to review studies reporting muscle biopsies from SSc patients with myositis and to identify unique histopathological features of SM.
Methods: A scoping review was conducted and included all studies reporting histopathological findings in SSc patients with myositis searching the following databases: PubMed, MEDLINE, EMBASE, CINAHL and EBM-Reviews. Clinical, serological, and histopathological data were extracted using a standardized protocol.
Results: Out of 371 citations, 77 studies that included 559 muscle biopsies were extracted. Fifty-seven percent (n = 227/400) had inflammatory infiltrates, predominantly T cells, which were endomysial (49%), perimysial (42%) and perivascular (41%). Few studies (18%, n = 8/44) evaluated the presence of B-cells. Myofiber atrophy was present in 48% (n = 104/218) of biopsies, and was predominantly perifascicular in 19% (n = 6/31), with necrosis reported in 56% (n = 162/290) of cases. Sarcolemmal MHC-I upregulation was found in 72% (n = 64/89) of biopsies. Non-specified C5b-9 deposition was described in 39% of muscle biopsies (n = 28/72). Neurogenic features were present in 23% (n = 44/191); endomysial fibrosis was reported in 35% (n = 120/340); and rimmed vacuoles were observed in 32% (n = 11/34) of biopsies. Capillaropathy, such as capillary dropout and/or ultrastructural endothelial abnormalities, was reported in 33% (n = 43/129) of cases. Reported ENMC categories were mainly polymyositis (21%), non-specific myositis (19%), immune-mediated necrotizing myopathy (16%), and dermatomyositis (8%). Histopathological features were analyzed according to serological subtypes in 28 studies, including anti-PM-Scl (n = 48), -Ku (n = 23) and -U1RNP (n = 90). Most of these biopsies demonstrated inflammatory infiltrates (range 49-85%) as well as MHC-I expression (range 63-81%). Necrosis was associated with anti-Ku (85%) and anti-U1RNP (73%), while anti-Ku was also associated with neurogenic features and rimmed vacuoles in 57% and 25% of cases, respectively.
Conclusion: Our review suggests that SM is characterized by heterogeneous pathological features using definitions included in current histopathological criteria. Whether a distinct histopathological signature exists in SM remains to be determined. SSc-specific and SSc-associated autoantibodies may help define more homogeneous histopathological subsets.
Keywords: Histopathology; Myositis; Scleroderma; Scleromyositis; Scoping review; Systemic sclerosis-associated myopathy.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Autoantibody profiles delineate distinct subsets of scleromyositis.Rheumatology (Oxford). 2022 Mar 2;61(3):1148-1157. doi: 10.1093/rheumatology/keab492. Rheumatology (Oxford). 2022. PMID: 34146090
-
Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078. eCollection 2022. Front Immunol. 2023. PMID: 36776390 Free PMC article. Review.
-
Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge.Autoimmun Rev. 2022 Feb;21(2):102993. doi: 10.1016/j.autrev.2021.102993. Epub 2021 Nov 16. Autoimmun Rev. 2022. PMID: 34798316 Review.
-
Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology.Arthritis Res Ther. 2014 May 13;16(3):R111. doi: 10.1186/ar4562. Arthritis Res Ther. 2014. PMID: 24886750 Free PMC article.
-
Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis.Neuropathol Appl Neurobiol. 2022 Dec;48(7):e12840. doi: 10.1111/nan.12840. Epub 2022 Aug 12. Neuropathol Appl Neurobiol. 2022. PMID: 35894636
Cited by
-
Scleromyositis: A Novel Entity Beyond Systemic Sclerosis and Autoimmune Myositis.Cureus. 2023 Aug 28;15(8):e44292. doi: 10.7759/cureus.44292. eCollection 2023 Aug. Cureus. 2023. PMID: 37779777 Free PMC article.
-
Full Recovery Over One Year of the Overlap Syndrome Scleromyositis to Maintenance Therapy with Mycophenolate Mofetil and Rituximab, which Relapsed within 8 Months of Discontinuation.Eur J Case Rep Intern Med. 2025 May 5;12(5):005154. doi: 10.12890/2025_005154. eCollection 2025. Eur J Case Rep Intern Med. 2025. PMID: 40352696 Free PMC article.
-
Systemic sclerosis associated myopathy: how to treat.Curr Treatm Opt Rheumatol. 2023 Dec;9(4):151-167. doi: 10.1007/s40674-023-00206-y. Epub 2023 Jul 19. Curr Treatm Opt Rheumatol. 2023. PMID: 38737329 Free PMC article.
-
The clinical features, muscle pathology, and role of autophagy in anti-Ku-positive patients.Front Immunol. 2025 Jun 17;16:1608735. doi: 10.3389/fimmu.2025.1608735. eCollection 2025. Front Immunol. 2025. PMID: 40599787 Free PMC article.
-
The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.Int J Mol Sci. 2022 Oct 9;23(19):12011. doi: 10.3390/ijms231912011. Int J Mol Sci. 2022. PMID: 36233313 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous